Curadel Surgical Innovations, Inc., doing business as Curadel Pharma, is a privately held Delaware biotechnology company headquartered in Bonita Springs, Florida. It holds exclusive global rights to the FLARE portfolio of near-infrared fluorescent contrast agents for image-guided surgery and is developing a zwitterionic radiopharmaceutical platform for targeted alpha therapy, with lead programs including the ZW800-1 surgical imaging drug in a Phase 3 pivotal trial and the CPI-003 therapeutic candidate. In January 2026 its CPI-008 pancreatic-cancer imaging drug received FDA and EMA orphan drug designations.
1
Round
1
Industry
5
Tags
Oct 13, 2026
Latest raise
Funding activity · 1 round
Oct 13, 2026
$49.8M
Series B
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
